Changes in Body Mass and Metabolic Profiles in Patients with First-Episode Schizophrenia Treated for 12 Months with A First-Generation Antipsychotic
Authors:
- 1 February 2015
- journal article
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 30 (2) , 277-283
Abstract
Objectives: To assess changes in body mass and metabolic profiles in patients with first-episode schizophrenia receiving standardised, assured treatment and to identify predictors and moderators of the effects.Methods: We investigated the changes in body mass, fasting blood glucose and lipids in 107 largely antipsychotic naïve, first-episode schizophrenia patients who were treated according to a standard algorithm with long-acting injectable flupenthixol decanoate over 12 months.Results: Eighty-three (78%) participants completed the 12 months of treatment, and 104 (97%) received 100% of the prescribed injections during their participation. There were significant increases in BMI (P < .0001), waist circumference (P = 0.0006) and triglycerides (P = 0.03) and decrease in HDL (P = 0.005), while systolic (P = 0.7) and diastolic blood pressure (P = 0.8), LDL (P = 0.1), cholesterol (P = 0.3), and glucose (P = 0.9) values did not change over time. The triglyceride: HDL ratio increased by 91%. Change in BMI was only correlated with change in triglycerides (P = .008). The only significant predictor of BMI increase was non-substance abuse (P = .002).Conclusions: The risks of weight gain and metabolic syndrome associated with antipsychotic treatment in first-episode schizophrenia are not restricted to second generation antipsychotics. This is a global problem, and developing communities may be particularly susceptible.Keywords
Funding Information
- New Partnership for Africa's Development (NEPAD)
- Department of Science and Technology of South Africa
- Medical Research Council of South Africa
- Lundbeck International
This publication has 40 references indexed in Scilit:
- Antipsychotic drugs and obesityTrends in Molecular Medicine, 2011
- Genome-wide analysis of the structure of the South African Coloured Population in the Western CapeHuman Genetics, 2010
- Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: Effect modification or regression to the mean?Psychiatry Research, 2009
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and AdolescentsJAMA, 2009
- Harmonizing the Metabolic SyndromeCirculation, 2009
- Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)European Psychiatry, 2009
- Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic DisordersCNS Drugs, 2008
- Medication adherence of individuals with a first episode of psychosisActa Psychiatrica Scandinavica, 2002
- The unhealthy lifestyle of people with schizophreniaPsychological Medicine, 1999
- Assessing Depression in Schizophrenia: The Calgary Depression ScaleThe British Journal of Psychiatry, 1993